Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Copyright 2021 Clarivate Analytics..
Acquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of fibrinogen in uncontrolled bleeding events is currently recommended by most published guidelines, suggesting treatment thresholds to maintain a minimum of 1.5 g/L plasma fibrinogen concentration for nonobstetrical hemorrhage. Fibrinogen concentrates, originally licensed for treatment of bleeding episodes in patients with congenital hypo-, dys- or afibrinogenemia disorders, are used in many clinical situations as supplementary therapy for the treatment of acquired hypofibrinogenemia. This review seeks to provide an overview of the most relevant topics associated to fibrinogen replacement therapy for critical perioperative hemorrhage highlighting currently available evidence on the risk/benefit profile of purified fibrinogen concentrates for this extended clinical indication.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
---|---|
Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 3 vom: 01. März, Seite 219-239 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Koller, T [VerfasserIn] |
---|
Links: |
---|
Themen: |
9001-32-5 |
---|
Anmerkungen: |
Date Completed 19.03.2021 Date Revised 19.03.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1358/dot.2021.57.3.3250287 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322858429 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322858429 | ||
003 | DE-627 | ||
005 | 20231225182931.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1358/dot.2021.57.3.3250287 |2 doi | |
028 | 5 | 2 | |a pubmed24n1076.xml |
035 | |a (DE-627)NLM322858429 | ||
035 | |a (NLM)33729219 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Koller, T |e verfasserin |4 aut | |
245 | 1 | 0 | |a Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.03.2021 | ||
500 | |a Date Revised 19.03.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright 2021 Clarivate Analytics. | ||
520 | |a Acquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of fibrinogen in uncontrolled bleeding events is currently recommended by most published guidelines, suggesting treatment thresholds to maintain a minimum of 1.5 g/L plasma fibrinogen concentration for nonobstetrical hemorrhage. Fibrinogen concentrates, originally licensed for treatment of bleeding episodes in patients with congenital hypo-, dys- or afibrinogenemia disorders, are used in many clinical situations as supplementary therapy for the treatment of acquired hypofibrinogenemia. This review seeks to provide an overview of the most relevant topics associated to fibrinogen replacement therapy for critical perioperative hemorrhage highlighting currently available evidence on the risk/benefit profile of purified fibrinogen concentrates for this extended clinical indication | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Bleeding disorders | |
650 | 4 | |a Blood factors | |
650 | 4 | |a Fibrinogen | |
650 | 4 | |a Fibrinogen replacement therapy | |
650 | 4 | |a Hemostatics | |
650 | 4 | |a Hypofibrinogenemia | |
650 | 4 | |a Plasma fibrinogen concentration | |
650 | 7 | |a Hemostatics |2 NLM | |
650 | 7 | |a Fibrinogen |2 NLM | |
650 | 7 | |a 9001-32-5 |2 NLM | |
700 | 1 | |a Parera Ruiz, A |e verfasserin |4 aut | |
700 | 1 | |a Diaz-Ricart, M |e verfasserin |4 aut | |
700 | 1 | |a Gómez Caro, A M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 3 vom: 01. März, Seite 219-239 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
773 | 1 | 8 | |g volume:57 |g year:2021 |g number:3 |g day:01 |g month:03 |g pages:219-239 |
856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.3.3250287 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 57 |j 2021 |e 3 |b 01 |c 03 |h 219-239 |